Lipid A and liposomes containing lipid A as antigens and adjuvants

Vaccine

Volumn 26, Issue 24, 2008, Pages 3036-3045

  Alving, Carl R ^a   Rao, Mangala ^a  

^a US Military HIV Research Program   (United States)

Author keywords

Adaptive immunity; Adjuvants; Antibodies to lipids; Endotoxin; HIV 1; Innate immunity; Lipid A; Lipopolysaccharide; Liposomes; Natural antibodies; Neutralizing antibodies; Polyreactive antibodies

Indexed keywords

ADJUVANT; BACTERIUM LIPOPOLYSACCHARIDE; CANCER VACCINE; CHOLESTEROL; DICETYL PHOSPHATE; DIPALMITOYLPHOSPHATIDYLCHOLINE; GAMMA INTERFERON; GLYCOPROTEIN GP 41; GLYCOSPHINGOLIPID; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPID A; LIPOSOME; MALARIA VACCINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PHOSPHATIDYLINOSITOL 4 PHOSPHATE; PHOSPHOLIPID; PHOSPHORYL LIPID A; SQUALENE; TOLL LIKE RECEPTOR 4; VACCINE;

ADAPTIVE IMMUNITY; ANTIGEN BINDING; ARTICLE; BACTERIAL CELL; BACTERIAL INFECTION; CLINICAL TRIAL; DRUG ACTIVITY; DRUG FORMULATION; DRUG STRUCTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNIZATION; IMMUNOGENICITY; INNATE IMMUNITY; LIPOSOMAL DELIVERY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; TRYPANOSOMA RHODESIENSE; VACCINATION; VIRUS ENVELOPE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CELLS, CULTURED; HIV ANTIBODIES; HIV-1; HUMANS; LIPID A; LIPOSOMES; MICE; PHOSPHATIDYLINOSITOL PHOSPHATES; TOLL-LIKE RECEPTOR 4; VACCINES;

EID: 44649198561     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.12.002     Document Type: Article

References (98)

1. Rietschel E.T., Kirikae T., Schade F.U., Mamat U., Schmidt G., Loppnow H., et al. Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J 8 2 (1994) 217-225
2. Caroff M., and Karibian D. Structure of bacterial lipopolysaccharides. Carbohydr Res 338 23 (2003) 2431-2447
3. Banerji B., and Alving C.R. Lipid A from endotoxin: antigenic activities of purified fractions in liposomes. J Immunol 123 (1979) 2558-2562
4. Mattsby-Baltzer I., and Alving C.R. Lipid A fractions analyzed by a technique involving thin-layer chromatography and enzyme-linked immunosorbent assay. Eur J Biochem 138 2 (1984) 333-337
5. Mattsby-Baltzer I., Gemski P., and Alving C.R. Heterogeneity of lipid A. Rev Infect Dis 6 4 (1984) 444-448
6. Brandenburg K., and Wiese A. Endotoxins: relationships between structure, function, and activity. Curr Top Med Chem 4 11 (2004) 1127-1146
7. Rietschel E.T., Galanos C., Tanaka A., Ruschmann E., Luderitz O., and Westphal O. Biological activities of chemically modified endotoxins. Eur J Biochem 22 2 (1971) 218-224
8. Westphal O. Bacterial endotoxins. The second Carl Prausnitz Memorial Lecture. Int Arch Allergy Appl Immunol 49 1-2 (1975) 1-43
9. Takada H., and Kotani S. Structural requirements of lipid A for endotoxicity and other biological activities. Crit Rev Microbiol 16 6 (1989) 477-523
10. Schuster B.G., Neidig M., Alving B.M., and Alving C.R. Production of antibodies against phosphocholine, phosphatidylcholine, sphingomyelin, and lipid A by injection of liposomes containing lipid A. J Immunol 122 3 (1979) 900-905
11. Banerji B., and Alving C.R. Anti-liposome antibodies induced by lipid A. I. Influence of ceramide, glycosphingolipids, and phosphocholine on complement damage. J Immunol 126 3 (1981) 1080-1084
12. Banerji B., Kenny J.J., Scher I., and Alving C.R. Antibodies against liposomes in normal and immune-defective mice. J Immunol 128 4 (1982) 1603-1607
13. Banerji B., and Alving C.R. Antibodies to liposomal phosphatidylserine and phosphatidic acid. Biochem Cell Biol 68 1 (1990) 96-101
14. Wassef N.M., Swartz Jr. G.M., Alving C.R., and Kates M. Antibodies to liposomal phosphatidylcholine and phosphatidylsulfocholine. Biochem Cell Biol 68 1 (1990) 54-58
15. Matyas G.R., Wassef N.M., Rao M., and Alving C.R. Induction and detection of antibodies to squalene. J Immunol Methods 245 1/2 (2000) 1-14
16. Banerji B., Lyon J.A., and Alving C.R. Membrane lipid composition modulates the binding specificity of a monoclonal antibody against liposomes. Biochim Biophys Acta 689 2 (1982) 319-326
17. Alving C.R. Antibodies to liposomes, phospholipids and phosphate esters. Chem Phys Lipids 40 2-4 (1986) 303-314
18. Wassef N.M., Roerdink F., Swartz Jr. G.M., Lyon J.A., Berson B.J., and Alving C.R. Phosphate-binding specificities of monoclonal antibodies against phosphoinositides in liposomes. Mol Immunol 21 10 (1984) 863-868
19. Alving B.M., Banerji B., Fogler W.E., and Alving C.R. Lupus anticoagulant activities of murine monoclonal antibodies to liposomal phosphatidylinositol phosphate. Clin Exp Immunol 69 2 (1987) 403-408
20. Wassef N.M., Swartz G.M., Alving B.M., and Alving C.R. ATP specifically bound as a hapten to a monoclonal anti-phospholipid antibody retains phosphate donor activity. Biochem Biophys Res Commun 190 2 (1993) 582-588
21. Stollar B.D., McInerney T., Gavron T., Wassef N.M., Swartz Jr. G.M., and Alvins C.R. Cross-reactions of nucleic acids with monoclonal antibodies to phosphatidylinositol phosphate and cholesterol. Mol Immunol 26 1 (1989) 73-79
22. Alving C.R., and Swartz Jr. G.M. Antibodies to cholesterol, cholesterol conjugates and liposomes: implications for atherosclerosis and autoimmunity. Crit Rev Immunol 10 5 (1991) 441-453
23. Swartz Jr. G.M., Gentry M.K., Amende L.M., Blanchette-Mackie E.J., and Alving C.R. Antibodies to cholesterol. Proc Natl Acad Sci USA 85 6 (1988) 1902-1906
24. Dijkstra J., Swartz Jr. G.M., Raney J.J., Aniagolu J., Toro L., Nacy C.A., et al. Interaction of anti-cholesterol antibodies with human lipoproteins. J Immunol 157 5 (1996) 2006-2013
25. Beutler B. Innate immunity: an overview. Mol Immunol 40 12 (2004) 845-859
26. Miller S.I., Ernst R.K., and Bader M.W. LPS, TLR4 and infectious disease diversity. Nat Rev Microbiol 3 1 (2005) 36-46
27. Miyake K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol 19 1 (2007) 3-10
28. Zimmer S.M., Zughaier S.M., Tzeng Y.L., and Stephens D.S. Human MD-2 discrimination of meningococcal lipid A structures and activation of TLR4. Glycobiology 17 8 (2007) 847-856
29. Raetz C.R., Garrett T.A., Reynolds C.M., Shaw W.A., Moore J.D., Smith Jr. D.C., et al. Kdo2-lipid A of Escherichia coli, a defined endotoxin that activates macrophages via TLR-4. J Lipid Res 47 5 (2006) 1097-1111
30. Pasare C., and Medzhitov R. Control of B-cell responses by Toll-like receptors. Nature 438 7066 (2005) 364-368
31. Jiang Z.H., and Koganty R.R. Synthetic vaccines: the role of adjuvants in immune targeting. Curr Med Chem 10 15 (2003) 1423-1439
32. Baldridge J.R., McGowan P., Evans J.T., Cluff C., Mossman S., Johnson D., et al. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther 4 7 (2004) 1129-1138
33. Gavin A.L., Hoebe K., Duong B., Ota T., Martin C., Beutler B., et al. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 314 5807 (2006) 1936-1938
34. Wickelgren I. Mouse studies question importance of Toll-like receptors to vaccines. Science 314 5807 (2006) 1859-1860
35. Nemazee D., Gavin A., Hoebe K., and Beutler B. Immunology: Toll-like receptors and antibody responses. Nature 441 7091 (2006) E4 (Discussion E4)
36. Pasare C., and Medzhitov R. Toll-like receptors and antibody responses (Reply). Nature 441 7091 (2006) E4 (Discussion E4)
37. Mata-Haro V., Cekic C., Martin M., Chilton P.M., Casella C.R., and Mitchell T.C. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316 5831 (2007) 1628-1632
38. Joseph C.K., Wright S.D., Bornmann W.G., Randolph J.T., Kumar E.R., Bittman R., et al. Bacterial lipopolysaccharide has structural similarity to ceramide and stimulates ceramide-activated protein kinase in myeloid cells. J Biol Chem 269 26 (1994) 17606-17610
39. Wright S.D., and Kolesnick R.N. Does endotoxin stimulate cells by mimicking ceramide?. Immunol Today 16 6 (1995) 297-302
40. Barber S.A., Detore G., McNally R., and Vogel S.N. Stimulation of the ceramide pathway partially mimics lipopolysaccharide-induced responses in murine peritoneal macrophages. Infect Immun 64 8 (1996) 3397-3400
41. Verma J.N., Rao M., Amselem S., Krzych U., Alving C.R., Green S.J., et al. Adjuvant effects of liposomes containing lipid A: enhancement of liposomal antigen presentation and recruitment of macrophages. Infect Immun 60 6 (1992) 2438-2444
42. Yokochi T., Inoue Y., Yokoo J., Kimura Y., and Kato N. Retention of bacterial lipopolysaccharide at the site of subcutaneous injection. Infect Immun 57 6 (1989) 1786-1791
43. Lacroix-Desmazes S., Kaveri S.V., Mouthon L., Ayouba A., Malanchere E., Coutinho A., et al. Self-reactive antibodies (natural autoantibodies) in healthy individuals. J. Immunol Methods 216 1/2 (1998) 117-137
44. Casali P., and Notkins A.L. CD5+ B lymphocytes, polyreactive antibodies and the human B-cell repertoire. Immunol Today 10 (1989) 364-368
45. Wing M.G. The molecular basis for a polyspecific antibody. Clin Exp Immunol 99 (1995) 313-315
46. Zhou Z.H., and Notkins A.L. Polyreactive antigen-binding B (PAB+) cells are widely distributed and the PAB+ population consists of both B-1+ and B-1- phenotypes. Clin Exp Immunol 137 (2004) 88-100
47. Notkins A.L. Polyreactivity of antibody molecules. Trends Immunol 25 (2004) 174-179
48. Martin F., and Kearney J.F. B-cell subsets and the mature preimmune repertoire. Marginal zone and B1 B cells as part of a "natural immune memory". Immunol Rev 175 (2000) 70-79
49. Cunningham A.J. Large numbers of cells in normal mice produce antibody components of isologous erythrocytes. Nature 252 (1974) 749-771
50. Cox K.O., and Hardy S.J. Autoantibodies against mouse bromelain-modified RBC are specifically inhibited by a common membrane phospholipid, phosphatidylcholine. Immunology 55 (1985) 263-269
51. Mercolino T.J., Arnold L.W., and Haughton G. Phosphatidyl choline is recognized by a series of Ly-1+ murine B cell lymphomas specific for erythrocyte membranes. J Exp Med 163 (1986) 155-215
52. Mercolino T.J., Arnold L.W., Hawkins L.A., and Haughton G. Normal mouse peritoneum contains a large population of Ly-1+ (CD5) B cells that recognize phosphatidyl choline. Relationship to cells that secrete hemolytic antibody specific for autologous erythrocytes. J Exp Med 168 (1988) 687-698
53. Mercolino T.J., Locke A.L., Afshari A., Sasser D., Travis W.W., Arnold L.W., et al. Restricted immunoglobulin variable region gene usage by normal Ly-1 (CD5+) B cells that recognize phosphatidyl choline. J Exp Med 169 (1989) 1869-1877
54. Kawaguchi S. Antiphospholipid antibodies reactive with bromelain-treated mouse erythrocytes in mice, rats and rabbits. Int Arch Allergy Appl Immunol 96 (1991) 46-50
55. Cabiedes J., Cabral A.R., and Alarcon-Segovia D. Hidden anti-phospholipid antibodies in normal human sera circulate as immune complexes whose antigen can be removed by heat, acid, hypermolar buffers or phospholipase treatments. Eur J Immunol 28 (1998) 2108-2114
56. Cabiedes J., Cabral A.R., Lopez-Mendoza A.T., Cordero-Esperon H.A., Huerta M.T., and Alarcon-Segovia D. Characterization of anti-phosphatidylcholine polyreactive natural autoantibodies from normal human subjects. J Autoimmun 18 (2002) 181-190
57. Fogler W.E., Swartz Jr. G.M., and Alving C.R. Antibodies to phospholipids and liposomes: binding of antibodies to cells. Biochim Biophys Acta 903 2 (1987) 265-272
58. Alving C.R. Antibodies to lipids and liposomes: immunology and safety. J Liposome Res 16 (2006) 157-166
59. Alving C.R., and Wassef N.M. Naturally-occurring antibodies to cholesterol: a new theory of LDL cholesterol metabolism. Immunol Today 20 (1999) 362-366
60. Richards R.L., Aronson J., Schoenbechler M., Diggs C.L., and Alving C.R. Antibodies reactive with liposomal phospholipids are produced during experimental Trypanosoma rhodesiense infections in rabbits. J Immunol 130 3 (1983) 1390-1394
61. Ferguson M.A., Low M.G., and Cross G.A. Glycosyl-sn-1, 2-dimyristylphosphatidylinositol is covalently linked to Trypanosoma brucei variant surface glycoprotein. J Biol Chem 260 27 (1985) 14547-14555
62. Vaarala O., Palosuo T., Kleemola M., and Aho K. Anticardiolipin response in acute infections. Clin Immunol Immunopathol 41 1 (1986) 8-15
63. Galanos C., Lüderitz O., and Westphal O. Preparation and properties of antisera against the lipid-A component of bacterial lipopolysaccharides. Eur J Biochem 24 1 (1971) 116-122
64. Kataoka T., Inouse K., Galanos C., and Kinsky S.C. Detection and specificity of lipid A antibodies using liposomes sensitized with lipid A and bacterial lipopolysaccharides. Eur J Biochem 24 1 (1971) 123-127
65. Miyazawa A., Umeda M., Horikoshi T., Yanagisawa K., Yoshioka T., and Inoue K. Production and characterization of monoclonal antibodies that bind to phosphatidylinositol 4,5-bisphosphate. Mol Immunol 25 10 (1988) 1025-1031
66. Brodin T., Thurin J., Strömberg N., Karlsson K.A., and Sjögren H.O. Production of oligosaccharide-binding monoclonal antibodies of diverse specificities by immunization with purified tumor-associated glycolipids inserted into liposomes with lipid A. Eur J Immunol 16 8 (1986) 951-956
67. Ramsey R.B., Hamner M.B., Alving B.M., Finlayson J.S., Alving C.R., and Evatt B.L. Effects of lipid A and liposomes containing lipid A on platelet and fibrinogen production in rabbits. Blood 56 2 (1980) 307-310
68. Richardson E.C., Banerji B., Seid Jr. R.C., Levin J., and Alving C.R. Interactions of lipid A and liposome-associated lipid A with Limulus polyphemus amoebocytes. Infect Immun 39 3 (1983) 1385-1391
69. Dijkstra J., Mellors J.W., Ryan J.L., and Szoka F.C. Modulation of the biological activity of bacterial endotoxin by incorporation into liposomes. J Immunol 138 8 (1987) 2663-2670
70. Dijkstra J., Larrick J.W., Ryan J.L., and Szoka F.C. Incorporation of LPS in liposomes diminishes its ability to induce tumoricidal activity and tumor necrosis factor secretion in murine macrophages. J Leukoc Biol 43 5 (1988) 436-444
71. Richards R.L., Swartz Jr. G.M., Schultz C., Hayre M.D., Ward G.S., Ballou W.R., et al. Immunogenicity of liposomal malaria sporozoite antigen in monkeys: adjuvant effects of aluminium hydroxide and non-pyrogenic liposomal lipid A. Vaccine 7 6 (1989) 506-512
72. Petrov A.B., Semenov B.F., Vartanyan Y.P., Zakirov M.M., Torchilin V.P., Trubetskoy V.S., et al. Toxicity and immunogenicity of Neisseria meningitidis lipopolysaccharide incorporated into liposomes. Infect Immun 60 9 (1992) 3897-3903 [Erratum in: Infect Immun 1992;60(12):5324]
73. Dijkstra J., Mellors J.W., and Ryan J.L. Altered in vivo activity of liposome-incorporated lipopolysaccharide and lipid A. Infect Immun 57 11 (1989) 3357-3363
74. Alving C.R. Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants. Immunobiology 187 3-5 (1993) 430-446
75. Vosika G.J., Barr C., and Gilbertson D. Phase-I study of intravenous modified lipid A. Cancer Immunol Immunother 18 2 (1984) 107-112
76. Fries L.F., Gordon D.M., Richards R.L., Egan J.E., Hollingdale M.R., Gross M., et al. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc Natl Acad Sci USA 89 1 (1992) 358-362
77. Heppner D.G., Gordon D.M., Gross M., Wellde B., Leitner W., Krzych U., et al. Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes. J Infect Dis 174 2 (1996) 361-366
78. Alving CR. Encapsulated high-concentration lipid A compositions as immunogenic agents to produce human antibodies to prevent or treat Gram-negative bacterial infections. US Patent 5,888,519 [issued March 30, 1999].
79. Samuel J., Budzynski W.A., Reddish M.A., Ding L., Zimmermann G.L., Krantz M.J., et al. Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine. Int J Cancer 75 2 (1998) 295-302
80. Harris D.T., Matyas G.R., Gomella L.G., Talor E., Winship M.D., Spitler L.E., et al. Immunologic approaches to the treatment of prostate cancer. Semin Oncol 26 4 (1999) 439-447
81. McElrath M.J. Selection of potent immunological adjuvants for vaccine construction. Semin Cancer Biol 6 6 (1995) 375-385
82. Gordon D.M., McGovern T.W., Krzych U., Cohen J.C., Schneider I., LaChance R., et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect Dis 171 6 (1995) 1576-1585
83. Alonso P.L., Sacarlal J., Aponte J.J., Leach A., Macete E., Milman J., et al. Efficacy of the RTS, S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364 9443 (2004) 1411-1420
84. Vandepapeli re P., Rehermann B., Koutsoukos M., Moris P., Garçon N., Wettendorff M., et al. Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults. Vaccine 23 20 (2005) 2591-2601
85. Kundi M. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines 6 2 (2007) 133-140
86. Moore J.P., Cao Y., Qing L., Sattentau Q.J., Pyati J., Koduri R., et al. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol 69 1 (1995) 101-109
87. McMichael A.J., and Hanke T. HIV vaccines 1983-2003. Nat Med 9 7 (2003) 874-880
88. McGaughey G.B., Barbato G., Bianchi E., Freidinger R.M., Garsky V.M., Hurni W.M., et al. Progress towards the development of a HIV-1 gp41-directed vaccine. Curr HIV Res 2 2 (2004) 193-204
89. Alving C.R., Beck Z., Karasavva N., Matyas G.R., and Rao M. HIV-1, lipid rafts, and antibodies to liposomes: implications for anti-viral-neutralizing antibodies. Mol Membr Biol 23 6 (2006) 453-465
90. Burton D.R., Desrosiers R.C., Doms R.W., Koff W.C., Kwong P.D., Moore J.P., et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5 3 (2004) 233-236
91. Haynes B.F., Fleming J., St Clair E.W., Katinger H., Stiegler G., Kunert R., et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308 5730 (2005) 1906-1908
92. Sánchez-Martínez S., Lorizate M., Hermann K., Kunert R., Basa ez G., and Nieva J.L. Specific phospholipid recognition by human immunodeficiency virus type-1 neutralizing anti-gp41 2F5 antibody. FEBS Lett 580 9 (2006) 2395-2399
93. Scherer E.M., Zwick M.B., Teyton L., and Burton D.R. Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity. AIDS 21 (2007) 2131-2139
94. Vcelar B., Stiegler g, Wolf H.M., Muntean W., Leschnik B., Mehandru S., et al. Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data. AIDS 21 (2007) 2161-2170
95. Alving CR. 4E10 and 2F5 monoclonal antibodies: binding specificities to phospholipids, tolerance, and clinical safety issues. AIDS 2008;22:1-3.
96. Haynes B.F., Moody M.A., Verkoczy L., Kelsoe G., and Alam S.M. Hum Antibodies 14 3/4 (2005) 59-67
97. Brown B.K., Karasavvas N., Beck Z., Matyas G.R., Birx D.L., Polonis V.R., et al. Monoclonal antibodies to phosphatidylinositol phosphate neutralize human immunodeficiency virus type 1: role of phosphate-binding subsites. J Virol 81 4 (2007) 2087-2091
98. Beck Z., Karasavvas N., Tong J., Matyas G.R., Rao M., and Alving C.R. Calcium modulation of monoclonal antibody binding to phosphatidylinositol phosphate. Biochem Biophys Res Commun 354 3 (2007) 747-751